Echo IQ Surges 38% on FDA Hopes, but Can a Company With A$91K in Revenue Justify a Near-Billion-Dollar Valuation?

Shares of Echo IQ rocketed 37.9% to A$1.71 on Wednesday, blowing past a week of flat trading near A$1.23, as speculative investors rushed to price in an imminent U.S. Food and Drug Administration decision on the company's AI-powered heart-failure diagnostic tool. The move pushes the pre-revenue Australian med-tech firm toward an implied market capitalisation above A$1.1 billion — a figure that demands scrutiny.

• The FDA Clock Is Ticking — And the Market Isn't Waiting. Echo IQ guided for an FDA decision on its heart-failure AI in the first half of 2026, meaning the ruling could land any day now.

The company lodged its 510(k) application — the standard pathway for medical devices — for its heart-failure clinical decision-support software. A clearance would be its second FDA green light, following approval for its aortic-stenosis (heart-valve narrowing) tool. That precedent is the main reason traders are betting yes, but a rejection or delay would gut the thesis overnight.

• Mayo Clinic Deal Signals Real Clinical Interest. Echo IQ expanded its agreement with the Mayo Clinic, one of the top-ranked U.S. hospital systems, to distribute its heart-failure AI through Mayo's network of 80-plus partner hospitals — contingent on FDA clearance.

Mayo also ran the validation studies, which showed the tool detected heart failure with 99.5% sensitivity and 91.1% specificity. Having a distribution partner lined up before approval shortens the gap between regulatory clearance and actual revenue.

• The Revenue Gap Is Enormous. In the last 12 months, Echo IQ booked just A$90,909 in revenue while posting A$15.71 million in losses.

Cash on hand sits at A$11.21 million with no debt. The bull case leans on a projection that if the company captures 25% of roughly six million annual U.S. echocardiograms under a new Medicare billing code, revenue could reach approximately US$106.5 million per year — but that is entirely theoretical at this stage.

• The Stock Is Already Priced for Success. Echo IQ has surged roughly 440% over the past 52 weeks.

Its market cap recently stood near A$892 million , and today's spike pushes it well beyond that. The average analyst price target is A$1.40, with a consensus "Strong Buy" rating — meaning the stock now trades above every published target. Investors are paying for a future that hinges entirely on one regulatory decision and years of hospital-by-hospital sales execution that hasn't yet begun in earnest.